M₁ muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease: Implications in future therapy

By Fisher Abraham   Pittel Zipora   Haring Rachel   Bar-Ner Nira   Kliger-Spatz Michal   Natan Niva   Egozi Inbal   Sonego Hagar   Marcovitch Itzhak   Brandeis Rachel  

Journal of Molecular Neuroscience, Vol. 20, Iss. 3, 2003-08 ,pp. : 349-356

Humana Press, Inc

Access to resources Recommend Favorite

Reduced High-Affinity Agonist Binding at the M 1 Muscarinic Receptor in Alzheimer's Disease Brain: Differential Sensitivity to Agonists and Divalent Cations

By Ladner C.J.   Lee J.M.  

Experimental Neurology, Vol. 158, Iss. 2, 1999-08 ,pp. : 451-458

Elsevier

Access to resources Recommend Favorite

The Utility of Muscarinic Agonists in the Treatment of Alzheimer's Disease

By Messer Jr. W.S.  

Journal of Molecular Neuroscience, Vol. 19, Iss. 1-2, 2002-10 ,pp. : 187-196

Humana Press, Inc

Access to resources Recommend Favorite

M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimer's Disease

By  

Current Alzheimer Research, Vol. 6, Iss. 2, 2009-04 ,pp. : 112-117

Bentham Science Publishers

Access to resources Recommend Favorite

Update on hypertension and Alzheimer's disease

By Skoog Ingmar   Gustafson Deborah  

Neurological Research, Vol. 28, Iss. 6, 2006-09 ,pp. : 605-611

Maney Publishing

Access to resources Recommend Favorite